In HBV-related HCC, miR-132 plays a role in tumor inhibition through the AKT signaling pathway, while HBx can inhibit its transcription by methylation of the enhancer in miR-132 to promote the occurrence and development of HCC (47). This evidence concerns the gene AKT1 and hepatocellular carcinoma.